Market Analysis - World Biomarkers 2017
The global market for cancer biomarkers was estimated to grow from $3.6 billion to $29.78 billion from 2007 by 2018 at an expected 14.60% CAGR (Compounded Annual Growth Rate) from 2011 when it was at $13.16 billion. Various factors such as the increasing demand for personalized medicine and companion diagnostics have enlarged the utility of biomarkers in the healthcare sector.
Biomarkers are any measurable characteristics of an organism that reflect a particular physiological state. In medicine, biomarkers are used as an indicator to find the disease presence or its severity. Biomarker research has gone further to new drug therapies, companion diagnostics and many other versatile fields. Demand for new biomarkers in different applications has boosted the biomarkers market.
Birmingham is one of the leading biomarker research centres in Europe. UK has good number of industries and research labs which work on biomarkers in various fields along with commercial production of them.
Members associated with Biomarker research:
Biomarker research is widely encouraged all over the world. Experts from various cross disciplines like oncology, pathology, proteomics, genomics, pharmacologists, doctors, clinicians and technology enlargement industries working in the field of biomarkers.
Hospitals associated with Biomarker research:
Various institutes and treatment facilities involved in cancer research and are intricate in cancer biomarker research all around the world. There are about 3976 hospitals in the world and 272 hospitals in UK which are prominent and working on biomarkers.
Societies associated with Biomarker research:
Biomarkers and cancer biomarkers are used in several disease diagnosis and treatment. Many eminent societies, associations and organizations are also taking part in the biomarker research. Some of them are,
- Alzheimer's Association
- American Brain Tumor Association
- American Society of Clinical Oncology
- Association for Molecular Pathology
- Cancer Research Society
- Cancer Research UK
- German Society for Oncological Pharmacy
- National Cancer Institute at the National Institutes of Health
- The ALS Association
- The British Association for Cancer Research
- The Canadian Cancer Society
- The International Society Of Oncology and Biomarkers
- The Swedish Cancer Society
Industries associated with Biomarker research:
Biomarkers are not permitted to labs but actually produced in commercial scale by many industries and used in prognosis, diagnosis, treatment etc.
Companies which play an important role in biomarker market in UK are,
- Blue Earth Diagnostics
- Erba MDX (Erba)
- Oxford Cancer Biomarkers
Companies from all over the world are,
- 20/20 Gene Systems
- Nuclea Biotechnologies
Universities associated with Biomarker research:
The majority of research is conducted in educational institutions by passionate groups of researches in numerous places throughout the world.
The top universities in Birmingham are,
- Abbey College Birmingham
- Aston University
- Matthew Boulton College
- University of Birmingham Medical School
- South & City College Birmingham
The top universities from rest of the world are,
- Stanford University
- Harvard University
- University of California, Los Angeles
- Yale University
- Weill Cornell Medicine
Market value on Biomarkers:
The present global market value of biomarkers is estimated to be $33 billion.
Nearly $7.32 billion is spent on the biotech industry in Europe in R&D and has $23.2 billion in revenue. About 20% of the total medicines marketed and almost 50% of all drugs in the pipeline are all products of healthcare biotech. About 95,000 people are provided employment by European biotech industry contributing to EU policies. When compared to the other EU members, UK accommodates maximum number of biotech-based companies which makes it the leading player in this market.
From $29.3 billion in 2013, the biomarkers market is anticipated to grow up to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.
In 2008 the UK pharmaceuticals market valued $54.7 billion and is expected to reach an approximate value of $65 billion by 2020 at a CAGR of 1.4%. The medical device market of UK was worth $18.9 billion in 2008 and is assessed to reach $34.4 billion in 2020 at a CAGR of 5.1%.
Products manufactured by the industries related to Biomarker Research and its market Value:
Numerous products are produced by industries for various uses like CTC technology, RNAi research tools, diagnostic tests and tools, separation systems and several other kits. These biomarker products have demanding market now. Some of them are having a great market value up to $17.1 billion and are expected to rise to $27.8 billion in near future.
Fund Allotment to Biomarker Research:
The Biomarker research has increased in double fold since it was first mentioned in 1973 in a research paper, also the funds allocated increased accordingly. NIH gave nearly $10.7 billion worth of grants to roughly 30,000 studies related to biomarker research, in which 10% are dedicated to just validation of biomarkers alone.
Other companies also funding the research with the increased market value. For example, a developer of novel prenatal screening tests company, Natera just announced an IPO with a $100 million goal. Natera’s revenue is $47.4 million, which raised from $27.2 million in 2014. Developers of novel cancer tests, Foundation Medicine, recently received an investment from Roche that increased the value of company over $2 billion.
Statistics of Physicians, Researchers and Academicians working on Biomarker Research:
The main individuals working on Biomarkers are academicians, researchers and physicians. There are plenty of people working on the biomarker research. In Birmingham alone there are 80 prominent persons working on biomarkers. There are about 5000 people In UK and about 40,000 eminent persons totally doing research related to biomarkers.
9th International Conference and Expo on Molecular & Cancer Biomarkers
Date: August 23-24, 2017
Venue: Birmingham, UK
Theme: Biomarkers: From labs to markets
- Clinical Researchers
- Cancer Researchers
- Young research
- Biomarker Associations and Societies
- Business Entrepreneurs
- Training Institutes
- Software developing companies
- Manufacturing Medical Devices Companies
- Data Management Companies
- Pharmaceutical Companies
- Diagnostics Companies